$PSNL

Tachibana Aaron sold $70K of PSNL

Tachibana Aaron (CFO AND COO) sold 4,982 shares of Personalis, Inc. (PSNL) at $14.00 on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tachibana Aaron
Published Jun 29, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 9:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PSNL
Neutral
medium confidence
Mentioned
$PSNL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PSNLNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new operating, financial, or regulatory information.

02

Market read

Traders may note insider selling, but the 10b5-1 structure reduces the likelihood of a fundamental re-rating.

03

What to watch

Insider sales can be tax- or diversification-driven; without additional context (e.g., concurrent buys, changes in guidance), the signal is weak.

Relevance 2/10Novelty 4/10Timing: today’s SEC Form 4 filing (2026-06-29)

Background

The article is an SEC Form 4 insider transaction disclosure for Personalis, Inc. (PSNL).

Company-level read

Ticker impact

$PSNLNeutralMedium confidence
Context

SEC Form 4 shows CFO/COO Tachibana Aaron sold 4,982 PSNL shares at $14.00 on 2026-06-29 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this disclosure.

Evidence & confidence

The filing is a scheduled open-market sale by a senior officer with an explicit pre-arranged 10b5-1 plan; transaction size is modest versus typical market-moving thresholds.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Because it’s a 10b5-1 plan, the sale may reflect liquidity planning rather than bearish expectations; any negative read-through may be overstated.

Key entities

  • Personalis, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Tachibana Aaron

    CFO and COO who executed the reported open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

$PSNLMed

Personalis (PSNL) Has Investors Asking A Fresh Question

Personalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

$TEMHighAI 9/10

Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant

Tempus AI agreed to acquire Personalis for $1.5B in July 2026. Personalis' tech supports Moderna and Merck's mRNA cancer vaccine, which showed positive Phase 3 results in August 2026. Tempus shares rose 23.91% on the news. Personalis' revenue grew 441.6% YoY in Q2 2026. Tempus reported $382.5M in Q2 2026 revenue, up 22% YoY. The deal is expected to close late Q4 2026 or early 2027.